255 related articles for article (PubMed ID: 29387966)
1. Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.
Mellone M; Gardoni F
J Neural Transm (Vienna); 2018 Aug; 125(8):1225-1236. PubMed ID: 29387966
[TBL] [Abstract][Full Text] [Related]
2. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
Rylander D; Recchia A; Mela F; Dekundy A; Danysz W; Cenci MA
J Pharmacol Exp Ther; 2009 Jul; 330(1):227-35. PubMed ID: 19357321
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia.
Pourmirbabaei S; Dolatshahi M; Rahmani F
Eur J Pharmacol; 2019 Jul; 855():149-159. PubMed ID: 31063776
[TBL] [Abstract][Full Text] [Related]
6. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
Sebastianutto I; Cenci MA
Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424
[TBL] [Abstract][Full Text] [Related]
7. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
8. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
[TBL] [Abstract][Full Text] [Related]
9. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
Schaeffer E; Pilotto A; Berg D
CNS Drugs; 2014 Dec; 28(12):1155-84. PubMed ID: 25342080
[TBL] [Abstract][Full Text] [Related]
11. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Duty S
CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
[TBL] [Abstract][Full Text] [Related]
12. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
14. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Marin C; Bonastre M; Aguilar E; Jiménez A
Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
[TBL] [Abstract][Full Text] [Related]
15. Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.
Marti M; Paganini F; Stocchi S; Mela F; Beani L; Bianchi C; Morari M
J Neurochem; 2003 Feb; 84(4):792-802. PubMed ID: 12562523
[TBL] [Abstract][Full Text] [Related]
16. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
[TBL] [Abstract][Full Text] [Related]
17. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
18. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
19. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
20. Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Lopez S; Bonito-Oliva A; Pallottino S; Acher F; Fisone G
J Parkinsons Dis; 2011; 1(4):339-46. PubMed ID: 23939343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
